Tangen Biosciences closes $9 million Series A

Tangen Biosciences has closed a $9 million Series A equity round led by Connecticut Innovations (CI), with participation of current and new stockholders, including VC23, Axiom, and Leading Edge Ventures.

The financing proceeds will be used to accelerate the company’s innovative platform TangenDx™ to the clinic for two infectious disease tests.